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The molecular mechanisms responsible for the
failure of antiangiogenic therapies and how tu-
mors adapt to these therapies are unclear. Here, we
applied transcriptomic, proteomic, andmetabolomic
approaches to preclinical models and provide evi-
dence for tumor adaptation to vascular endothelial
growth factor blockade through a metabolic shift
toward carbohydrate and lipidmetabolism in tumors.
During sunitinib or sorafenib treatment, tumor
growth was inhibited and tumors were hypoxic and
glycolytic. In sharp contrast, treatment withdrawal
led to tumor regrowth, angiogenesis restoration,
moderate lactate production, and enhanced lipid
synthesis. This metabolic shift was associated
with a drastic increase in metastatic dissemination.
Interestingly, pharmacological lipogenesis inhibition
with orlistat or fatty acid synthase downregulation
with shRNA inhibited tumor regrowth and metasta-
ses after sunitinib treatment withdrawal. Our data
shed light on metabolic alterations that result in can-
cer adaptation to antiangiogenic treatments and
identify key molecules involved in lipid metabolism
as putative therapeutic targets.
INTRODUCTION
Antiangiogenic agents currently used in clinic target the vascular
endothelial growth factor (VEGF) signaling pathway via an anti-
VEGF antibody (bevacizumab, Avastin) or small-molecule re-
ceptor tyrosine kinase inhibitors (RTKIs). Anti-VEGF antibodies
lead to increased overall survival or progression-free survival
in patients with metastatic colorectal cancer, non-small cell
lung cancer, or breast cancer when administered in combination
with conventional chemotherapeutic regimens (Jain et al., 2006).
Sunitinib (Sutent, Pfizer), a multi-RTKI that targets VEGF recep-
tors, platelet-derived growth factor (PDGF) receptor, and cKIT,280 Cell Metabolism 20, 280–294, August 5, 2014 ª2014 Elsevier Incalso provides clinical benefit to patients with renal cell carci-
noma or advanced gastrointestinal stromal tumors (GISTs)
(Adams and Leggas, 2007; van der Veldt et al., 2008). Sorafenib
(Nexavar, Bayer and Onyx), another antiangiogenic RTKI that
also displays inhibitory activity toward Raf kinase, has been
approved for the treatment of renal cell carcinoma and liver can-
cer (Wu et al., 2008). Overall, the survival benefits of antiangio-
genic drugs have been relatively modest, and surprisingly,
most cancer patients stop responding or do not respond at all
to antiangiogenic therapy (Ebos and Kerbel, 2011). Alarmingly,
preclinical studies have reported increased tumor growth
and metastatic formation after the withdrawal of treatment
with VEGF receptor inhibitors, including sunitinib (Ebos et al.,
2009a; Pa`ez-Ribes et al., 2009), a monoclonal antibody against
VEGFR2 (DC101), or a polyclonal antibody against VEGF (Sen-
nino et al., 2012). This tumor evasion of antiangiogenic treatment
appears to be dose dependent and tumor model dependent
(Singh et al., 2012; Welti et al., 2012). Whether tumor regrowth
can occur when therapy is stopped is an important clinical issue,
and several studies have raised pertinent questions about how
best to use antiangiogenic drugs (Bruce et al., 2014; Griffioen
et al., 2012). A deeper understanding of tumor responses to anti-
angiogenic therapy and the mechanisms by which resistance is
acquired is urgently needed. The poor response to anti-VEGF
monotherapy is likely due to the occurrence of multiple adaptive
processes as a result of a multitude of resistance mechanisms
that occur in both tumor cells and the tumor microenvironment
(Sounni and Noel, 2013). VEGF blockade can be compensated
by an increased production of alternative angiogenic factors
(Ebos et al., 2009b). Other mechanisms include the recruitment
of vascular progenitors, HIF-1a-induced autophagy, and cancer
stem cell pool expansion (Ebos et al., 2009b; Giuliano and
Page`s, 2013; Sounni and Noel, 2013). In addition, cancer cells
differ from normal cells regarding how their metabolic pathways
are used to fuel cellular growth and survival. Metabolic adapta-
tion in cancer is supported by clinical studies that have linked
altered whole-body metabolism to cancer development and
progression and poor treatment outcomes (Vander Heiden,
2011). Whether a metabolic switch contributes to the poor
response of tumors to antiangiogenic treatment has not been
determined..
(legend on next page)
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proaches, we provide evidence for a metabolic shift of tumors
to de novo lipogenesis following RTKI treatment withdrawal,
which is associated with rapid tumor regrowth and accelerated
metastatic dissemination. The functional implications of lipo-
genesis and fatty acid synthase (FASN) in this process
are supported by the blockade of tumor relapse through the
inhibition or downregulation of FASN with orlistat or shRNA,
respectively. Our data support the innovative concept of using
metabolic pathway inhibitors to sensitize tumors to antiangio-
genic drugs.
RESULTS
Withdrawal of Angiogenesis Inhibitor Treatment
Accelerates Tumor Growth and Metastasis
We applied several treatment regimens to a metastatic model of
human breast cancer involving MDA-MB-231 xenografts. Long-
term treatment with sunitinib at a therapeutic dose of 40 mg/kg
for 30 days resulted in a drastic inhibition of primary tumor
growth and metastasis formation (Figure 1A). By contrast,
short-term pretreatment with sunitinib 9 days prior to subcu-
taneous (s.c.) injection of tumor cells affected neither tumor
growth nor metastasis (Figures S1A and S1B, available online).
We next evaluated the effects of long-term treatment with suni-
tinib followed by treatment withdrawal (W-sunitinib) (Figures 1B
and 1C). As expected, whereas primary tumors responded
effectively to sunitinib during the treatment period, treatment
withdrawal resulted in accelerated tumor regrowth (Figures
1B). Indeed, sunitinib treatment resulted in tumor growth inhibi-
tion, as characterized by a stabilization of tumor volumes to
approximately 50–70 mm3 during the entire treatment period.
After sunitinib withdrawal tumors regrew rapidly, reaching a
volume of 300 mm3 5-fold faster than vehicle-treated tumors
(7 days for W-sunitinib tumors versus 35 days for control tu-
mors) (Figure 1E). Moreover, sunitinib withdrawal resulted in
increased metastasis in organs of mice sacrificed when tumors
reached the volume of the tumors of the vehicle group
(400 mm3) (Figure 1B, lower panel). A drastic increase in metas-
tases was also seen by bioluminescence and immunohisto-
chemical (IHC) staining of organs (lung, brain, and lymph nodes)
(Figures 1B and 1C). Similar results were obtained after the
withdrawal of treatment with sorafenib (W-sorafenib), another
RTKI approved for antiangiogenic therapy (Strumberg, 2005)
(Figures 1D and 1E). This drastic acceleration of tumor regrowth
and metastatic dissemination suggests a selection of aggres-Figure 1. Long-Term Sunitinib Treatment Increases a Tumor Regrowth
during the Treatment
MDA-MB-231 LUC+ cells were subcutaneously injected in RAG1/ mice.
(A) Evolution of tumor volumes in mice treated daily with vehicle or sunitinib
quantification of bioluminescence in organs (lower).
(B) Evolution of tumor volumes in mice treated with vehicle or sunitinib and follo
bioluminescence (images in bottom panel) and quantified (graph in middle panel
(C) Representative immunohistochemical images visualizing micrometastases b
Scale bar, 100 mm.
(D) Evolution of tumor volumes in mice treated daily with vehicle or sorafenib (50 m
line) (top) and quantification of bioluminescence in organs (bottom).
(E) Representative table showing a shorter latency period to reach a volume of 3
Data are presented as mean ± SD for tumor growth and mean ± SEM for biolum
282 Cell Metabolism 20, 280–294, August 5, 2014 ª2014 Elsevier Incsive tumor cells or an adaptation of the tumors to RTK inhibitor
withdrawal.
The Evaluation of Cancer Hallmarks in Primary Tumors
Reveals a Metabolic Shift after Antiangiogenesis
Treatment Withdrawal
To determine if histopathological features of primary tumors
were altered in response to antiangiogenesis treatment cessa-
tion, IHC analyses of key hallmarks of cancer progression (angio-
genesis, inflammation, matrix, and metabolism) were conducted
at the end of the assay when the vehicle and W-sunitinib tumors
both reached a volume of 400 mm3. We did not observe a differ-
ence in CD31 staining, a marker of angiogenesis, between the
two tumor types. Computerized quantification of vessel density
and distribution from the border to the center of the tumors re-
vealed a similar pattern in both experimental groups (Figure S2A).
Thus, angiogenesis was fully restored after sunitinib withdrawal.
However, the density and distribution of vessels positive for
a-smooth muscle actin (a-SMA) were twice as high as those in
the W-sunitinib group, indicating an increase in vessel matura-
tion after sunitinib withdrawal (Figure S2B). No difference in tu-
mor lymphangiogenesis and inflammatory infiltrates was seen
(Figures S2C and S2D). The analysis of matrix deposition by
saffron staining did not reveal any difference in the collagen den-
sity and distribution between W-sunitinib and vehicle tumors
(Figure S2E).
Recent preclinical studies have identified several mechanisms
of tumor adaptation to antiangiogenic agents, including the
compensatory production of alternative proangiogenic factors
(Ebos et al., 2009b; Sounni and Noel, 2013). As an initial attempt
to identify putative alternative factors, we analyzed the mRNA
expression levels of major pro-lymph/angiogenic and pro-
invasive molecules in W-sunitinib and control tumors (Fig-
ure S2F). Notably, VEGF-A, VEGF-C, HIF-1a, PAI-1, MMP-11,
and MMP-13 were expressed at similar levels. We then applied
global transcriptomic and proteomic analyses to compareW-su-
nitinib and vehicle tumors. Gene profiling using whole-genome
mouse microarrays indicated that sunitinib withdrawal induced
the modulation of around a hundred genes (Supplemental
Information, microarray_W-sunitinib). Interestingly, one of the
main relevant networks identified by ingenuity pathway analysis
(IPA) was related to carbohydrate metabolism and, notably, lipid
metabolism/regulation (Figure 2A).
For proteomic analysis, total tumor extracts were analyzed by
mass spectrometry. Again, amarkedmetabolic shift appeared in
W-sunitinib tumors, as reflected by the modulation of enzymesand Metastatic Dissemination after Treatment Withdrawal, but Not
(40 mg/kg) (D-sunitinib) for 30 days (as indicated by dashed line) (top) and
wed by sunitinib withdrawal (W-sunitinib) (top). Metastases were detected by
) after sunitinib withdrawal.
y immunostaining for human Ki67 in organs of the W-sunitinib-treated group.
g/kg) followed by sorafenib withdrawal (W-sorafenib) (as indicated by dashed
00 or 400 mm3 in W-sunitinib and W-sorafenib groups.
inescence quantification in organs. p% 0.05.
.
Figure 2. Sunitinib Treatment Withdrawal Results in a Cancer Metabolic Shift Identified by Transcriptomics, Proteomics, and Metabolomics
Analyses
(A) Representative table of the relevant mouse genes analyzed by RNA microarray of primary W-sunitinib tumors compared with vehicle-treated tumors. The
transcriptional profiling showed an upregulation of genes associated with carbohydrate and lipid metabolism. The diagram represents an ingenuity network
representation of the main upregulated (red) and downregulated (green) gene network.
(B) Proteomic analysis of primary tumors by mass spectrometry for human and mouse proteins. Relative protein quantity variations upon sunitinib treatment and
withdrawal in primary tumors are indicated as fold change obtained from the ratio of vehicle/W-sunitinib. *p% 0.05; **p% 0.01. Sunitinib treatment withdrawal
(legend continued on next page)
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Cancer Metabolism Shift and Antiangiogenic Drugsassociated with the citric acid cycle (TCA), lactate regulation,
and lipid transporters (Figure 2B). Intriguingly, many glycolytic
enzymes were downregulated in W-sunitinib tumors compared
with control tumors. These modifications were similar when
considering human and mouse proteins, suggesting a metabolic
adaptation in both host and tumor compartments (Figure 2B).
Thus, the metabolic perturbations observed by proteomic and
transcriptomic analyses appeared to boost fatty acid, pyruvate,
and amino acid metabolisms, whereas glucose metabolism and
cellular carbohydrate catabolism were downregulated by suniti-
nib withdrawal (Figure 2C). Furthermore, the identification of
metabolic end products in tumor extracts by nuclear magnetic
resonance (NMR) (Figure 2D) and scores plot analysis revealed
a clear difference in metabolites between vehicle and W-suniti-
nib tumors. The main discriminants identified through this me-
tabolomics approach correspond to lactate and lipids.
The mRNA levels of several genes in the metabolic network
were validated by RT-PCR analysis. Upon sunitinib withdrawal,
we observed increased mRNA levels of FASN, a key enzyme
in de novo lipogenesis that condenses malonyl coenzyme A
(malonyl-CoA) and acetyl-CoA into a long-chain fatty acid (Fig-
ure 3A). The expression of acetyl-CoA carboxylase (ACC-a),
the enzyme that transforms acetyl-CoA into malonyl-CoA, was
also enhanced. Similar modulations were detected using spe-
cific human and mouse primers (Figure S3A), suggesting that
de novo lipogenesis is triggered in both the tumor microenviron-
ment and cancer cells. The shift to lipid metabolism was further
supported by increased expression of adiponectin and perilipin
mRNAs. Western blot analysis of FASN and ACC-a confirmed
their increased levels in W-sunitinib tumors, while no difference
was seen in ACC-a phosphorylation status (Figure 3B). The pro-
duction of PPARg, a factor regulating lipid beta-oxidation, was
not affected by sunitinib withdrawal (Figure 3B). These data
underline a metabolic reprogramming toward de novo lipogen-
esis to sustain cancer growth and invasion. Furthermore,
increased FASN production and lipid droplet amounts inW-suni-
tinib tumors is supported by IHC stainings using antibodies
against FASN and perilipin, a marker of adipocytes (Figures 3C
and 3D). A computerized quantification performed on whole-
tumor sections confirmed the increased abundance of lipid
droplets throughout the tumors (Figure 3D). Enhanced deposi-
tion of collagen type VI produced mainly by adipocytes was
also detected (Figure 3E). Thus, W-sunitinib tumors were char-
acterized by substantial adipocyte infiltration and/or differentia-
tion. Notably, FASN, ACC-a, and perilipin modulations at mRNA
and protein levels were also increased in W-sorafenib tumors
(Figures 3F–3H).leads to an upregulation of lipid metabolism, lactate regulation, and TCA enzym
regulation (blue).
(C) Schematic diagram summarizing the bioinformatics analysis of the proteomi
withdrawal: (1) glycolysis (17%), (2) cellular carbohydrate catabolic process (17%
monosaccharide metabolic process (16%), (6) cellular macromolecule catabolic
rivative metabolic process (4%), (9) glutathione metabolic process (4%). The right
metabolism (14%), (3) pyruvate metabolism (14%), (4) pentose phosphate pathwa
methionine metabolism (10%), (7) arginine and proline metabolism (10%), (8) a
D-glutamine and D-glutamate metabolism (5%). Proteomic profiling with mass sp
from W-sunitinib and three tumors from vehicle-treated mice. Changes in transc
(D)Metabolic analysis by NMRof primary tumors treatedwith vehicle (V1-9) or afte
the principal component analysis (PCA) model. Main discriminant metabolites ar
284 Cell Metabolism 20, 280–294, August 5, 2014 ª2014 Elsevier IncCancer Cell Metabolism Is Differentially Altered during
and after the Withdrawal of Treatment with
Angiogenesis Inhibitors
The adaptation of tumormetabolism to lipogenesis inW-sunitinib
tumors prompted us to analyze the metabolic profile of tumors
during a period of sustained treatment with sunitinib (D-sunitinib)
(Figure S3B). Lipogenesis was decreased rather than increased
during sunitinib treatment. The expression of perilipin and
FASN in mice was drastically reduced in D-sunitinib tumors,
and no difference was found in the expression levels of human
FASN and ACC-a. As assessed by NMR, an enhancement of
lactate production was detected and was higher in D-sunitinib
than in W-sunitinib tumor extracts (5-fold versus 1.7-fold as
compared to control tumors) (Figure 4A). Carbonic anhydrase-
IX (CA-IX) staining revealed increased hypoxia during sunitinib
treatment (Figure 4B), but not after its withdrawal (Figure S4A).
Interestingly, the expression of monocarboxylate transporter 1
of lactate (MCT1) was enhanced in both D-sunitinib and W-suni-
tinib tumors, whereas MCT4 expression was induced only in
D-sunitinib tumors (Figures 4C–4E). Taken together, these obser-
vations suggest that during sunitinib treatment, tumors become
more glycolytic. By contrast, after treatment cessation, tumors
may be fueled by lipid metabolism and increased TCA activity.
Accordingly, the levels of twomajor regulators of pyruvate dehy-
drogenase (PDH) activity, pyruvate dehydrogenase kinases 1/2
(PDK1 and PDK2), were increased in D-sunitinib tumors (Fig-
ure 4F), indicating a reduction/inhibition of pyruvate oxidative
decarboxylation, which fuels the TCAcycle in D-sunitinib tumors.
In sharp contrast, upon sunitinib withdrawal, glycolysis was
reduced,PDK1andPDK2expressionwasdecreased (Figure4G),
and TCA activity was increased in W-sunitinib (Figures 4B and
4C). Consistently, PDK1 protein levels were decreased in W-su-
nitinib tumors (Figure S4B). Accordingly, the in vitro treatment of
MDA-MB-231 cells with sunitinib resulted in increased lactate
production in cell media and extracts and correlated with a
marked increase in glucose uptake by cells (Figure 5A). Similar
results were generated in breast (BT-549) and colorectal (HCT-
116) cancer cells treated with sunitinib or sorafenib (Figures 5A
and 5B). MCT4, PDK1, and PDK2 expression levels were
also induced after treatment with both RTKIs (Figures 5C and
5D). Notably, MCT1 is not produced by MDA-MB-231 cells
under basal conditions; its expression is induced upon RTKI
treatment. We next extended our investigation to stromal cells
(Figures 5E–5G). Lactate production and glucose uptake were
enhanced >1.5-fold in endothelial cells (HUVECs) (Figures 5E
and 5F). This correlates with increased mRNA levels of PDK1
and PDK2 expression, whereas the expression of MCT4,es (orange, gray, and red, respectively) and to a downregulation of glycolysis
c data. The left circle corresponds to downregulated pathways after sunitinib
), (3) glucosemetabolic process (16%), (4) hexose metabolic process (16%), (5)
process (6%), (7) cellular protein metabolic process (4%), (8) amino acid de-
circle corresponds to upregulated pathways: (1) TCA cycle (19%), (2) fatty acid
y (9%), (5) alanine, aspartate, and glutamate metabolism (9%), (6) cysteine and
dipocytokine signaling pathway (5%), (9) tyrosine metabolism (5%), and (10)
ectrometry was performed on total protein extracts from three different tumors
riptomic and proteomic data are obtained in 100% tumor samples.
r sunitinib withdrawal (W-S1-9). Score plots are shown for PC1 versus PC2 from
e shown below.
.
(legend on next page)
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Cancer Metabolism Shift and Antiangiogenic DrugsMCT1, or FASN was not affected (Figure 5G). A similar effect on
lactate production and glucose consumption was observed
upon 48 hr of RTKI treatment of cancer-associated fibroblasts
(CAFs) isolated from MMTV-PyMT mice (Figures 5E and 5F).
Angiogenesis Inhibitor Treatment Withdrawal Induces
TumorRegrowth and aMetabolic Shift in SeveralModels
of Cancer
RAG1/ mice bearing human colorectal HT-29 tumors of
70 mm3 were treated with sunitinib (40 mg/kg/day) for 30 days
(Figure 6A). Again, tumor growth was inhibited during the period
of sunitinib treatment, and accelerated tumor regrowth was
observed after treatment cessation. The tumor volumes
increased from 70 mm3 to 800–900 mm3 within 10 days after su-
nitinib withdrawal. Control tumors required twice as much time
to reach a similar volume (Figure 6A). Metastasis formation
was also drastically increased (right panel). Moreover, lactate
quantification revealed a 4-fold increase of this metabolite in
W-sunitinib tumors (Figure 6B). FASN density on tumor sections
was again increased inW-sunitinib HT-29 tumors comparedwith
vehicle-treated ones (Figure 6C). Lactate production and
glucose uptake increased significantly in vitro after RTKI treat-
ments (Figures 6D), recapitulating the response observed in
the other cell lines tested (Figure 5).
An oncogenic mouse model of mammary carcinoma was also
used. MMTV-PyMT mice (55 days old) bearing mammary tu-
mors of 50–75 mm3 were treated with sunitinib (n = 7) or vehicle
(n = 6) for 21 days (from day 55 to 76) followed by sunitinib with-
drawal for 17 days (Figure 6E). Sunitinib administration inhibited
tumor development during the treatment period, whereas suni-
tinib withdrawal was associated with a faster tumor growth and
rapid apparition of more numerous tumors when compared to
vehicle-treated mice. Indeed, treatment withdrawal led to the
apparition of tumors >5 mm within 12 days, while it took almost
88 days to reach this volume for fewer tumors in vehicle-treated
animals (Figure 6E). Lung metastasis was also drastically
increased after suninitib withdrawal, as revealed by hematoxylin
and eosin (H&E) staining of lung sections and computerized
quantification of metastasis size on whole-lung sections (Fig-
ure 6F). Importantly, an upregulation of lipid metabolism-asso-
ciated genes, including perilipin, adiponectin, and FASN, was
revealed by RT-PCR analyses (Figure S5A). The increase in
FASN production was further validated by IHC staining on tu-
mor sections (Figure 6G). The modulation of lactate production
and glucose consumption in cancer cells isolated from MMTV-
PyMT tumors was also confirmed in vitro upon RTKI treat-
ments (Figure S5B). Taken together, these data validate ourFigure 3. Cancer Adaptation to Sunitinib or Sorafenib Treatment Withdr
(A) RT-PCR analysis of mouse (m) and/or human (h) mRNA levels of fatty acid sy
W-sunitinib compared to vehicle-treated tumors (1–5; five individual tumor sample
levels normalized to ribosomal 28S.
(B) Western analysis of phosphorylated ACC (S79), total ACC, FASN, and PPAR
(C–E) Immunohistological images of primary tumors stained with antibody to FA
density and distance distribution from tumor edge to the center in whole-tumor
100 mm.
(F) RT-PCR analysis of mouse (m) and/or human (h) mRNA levels of FASN, adipon
(1–5; five individual tumor samples are shown). The graphs on the right correspo
(G and H) Immunostaining on tumor sections of FASN (G) and perilipin (H). The g
*p% 0.05; **p% 0.01; ***p% 0.005.
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RTKI administration.
The Adaptation to Angiogenesis Inhibitor Treatment
Withdrawal Is Reversed by FASN Blockade in Several
Cancer Models
Our findings indicate ametabolic adaptation of tumors to antian-
giogenic therapy that differs during and after treatment with su-
nitinib (Figure 6H). Glycolysis was induced during the treatment,
and lipid metabolism was associated with a more aggressive
phenotype after antiangiogenic therapy withdrawal. We hypoth-
esized that interfering with lipid metabolism via FASN inhibition
after sunitinib treatment might overcome this tumor adaptation
and block the associated metastatic dissemination. Our working
hypothesis was first evaluated by using orlistat, a pharmacolog-
ical inhibitor of FASN. Mice were separated in four experimental
groups: (1) vehicles for sunitinib and orlistat (Vehicle S/O); (2)
orlistat and the vehicle for sunitinib (Orlistat + vehicle S); (3) suni-
tinib as a single agent and the vehicle for orlistat (W-sunitinib +
VehicleO); and (4) orlistat after sunitinibwithdrawal (W-sunitinib +
orlistat).
Treatment with orlistat significantly reduced tumor growth at
an early stage of MDA-MB-231 tumor development (Figure 7A).
However, this treatment had no effect at later stages, and by the
end of the treatment tumors reached the volume of vehicle-
treated tumors. As expected, treatment with sunitinib inhibited
tumor growth during the treatment period, followed by a rapid
regrowth after sunitinib withdrawal. Interestingly, orlistat treat-
ment following sunitinib withdrawal reduced tumor regrowth
and inhibited metastasis formation (Figure 7B). Since mice
administered with orlistat displayed a reduction in body weight
of 5%–10% after 21 days of treatment (Figure 7A), we checked
whether orlistat could affect the whole-body metabolism by
applying a metabolomic approach to mice sera. The global
metabolic profiles of mice sera were indistinguishable between
the experimental groups (Figure 7C). Orlistat treatment of W-su-
nitinib tumors reduced lactate production and normalized its
level to vehicle- and orlistat-treated tumors (Figure 7D). Comput-
erized quantification of IHC stainings revealed a strong inhibition
of FASN and perilipin production upon orlistat treatment (Fig-
ure 7E). As expected, CA-IX stainings were similar in the four
experimental groups (Figure 7E).
We next extended our investigation to four additional models,
including colorectal HT29 xenografts, syngeneic models of
4T1 tumors heterotopically (s.c.) or orthotopically (in the mam-
mary fat pad, MFP) implanted in Balb/c mice, and Lewis lung
carcinoma (LLC) s.c. injected into C57BL6 mice (Figure S6).awal Is Strongly Linked to aMetabolic Shift toward LipidMetabolism
nthase (FASN), adiponectin, perilipin, and acetyl-CoA carboxylase (ACC-a) in
s are shown). The graphs on the right correspond to the quantification of mRNA
g. HSC70 and actin are used as loading controls.
SN (C), perilipin (D), and collagen type VI (E). Computerized quantification of
sections are shown below the images (n = 15 tumors per group). Scale bar,
ectin, perilipin, and ACC-a in W-sorafenib compared to vehicle-treated tumors
nd to the quantification of mRNA levels normalized to ribosomal 28S.
raphs correspond to quantification performed as described above.
.
Figure 4. Cancer Metabolism Shifts fromHypoxia andGlycolysis during Sunitinib Treatment to Normoxia and a Reduction of Glycolysis after
Sunitinib Withdrawal
(A) Lactate production in tumors was measured by NMR after treatment for 30 days with sunitinib (D-sunitinib) and after withdrawal (W-sunitinib).
(B and C) Images of immunohistochemical stainings with carbonic anhydrase (CA)-IX (B) and MCT1 (C) antibodies and their quantifications (graph) in D-sunitinib
tumors. The graphs represent a computerized quantification in whole-scanned tumor sections of each staining. Results are presented as staining density (top
graphs) and as distribution from the tumor edge to the center (bottom graphs). n = 12 tumors per group. Scale bar, 100 mm.
(D–G) RT-PCR analysis of expression levels of lactate transporters MCT1 and MCT4 in tumors during (D) and after (E) sunitinib treatment withdrawal. RT-PCR
analysis of mRNA expression levels of PDK1 and PDK2 in tumors during (F) and after (G) sunitinib treatment withdrawal. n = 5 per group. *p% 0.05; **p% 0.01;
***p% 0.005.
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associated with increased tumor regrowth and metastasis,
which can be completely reversed by the subsequent treatment
with orlistat.
To achieve a specific FASN inhibition in the tumor compart-
ment, MDA-MB-231 cells were stably transfected with control
shRNA (shCTR) or shRNA targeting FASN (shFASN) (Figures
7F–7I). Although the downregulation of FASN in untreated mice
(shFASN vehicle) delayed the onset of tumor development
in vivo, at the end of the assay these tumors reached volumes
similar to those of vehicle-treated tumors. Interestingly, the tu-
mor regrowth observed after sunitinib withdrawal did not occurCelin FASN downregulated tumors (shFASN W-sunitinib), and the
metastatic dissemination was completely abolished (Figures
7G–7I). Overall, these data clearly demonstrate that FASN activ-
ity in cancer cells is a rate-limiting event for themalignant pheno-
type observed after drug withdrawal. These experiments clearly
show that interfering with tumor FASN is sufficient to overcome
the tumor aggressiveness induced by drug withdrawal.
DISCUSSION
Herein, we provide mechanistic insights into how tumors adapt
their metabolism to VEGF-based antiangiogenic treatment.l Metabolism 20, 280–294, August 5, 2014 ª2014 Elsevier Inc. 287
(legend on next page)
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Cancer Metabolism Shift and Antiangiogenic DrugsGlobal transcriptomic, proteomic approaches, as well as histo-
chemical, biochemical, and NMR analyses, revealed a shift to-
ward lipid metabolism and increased TCA activity to fuel cancer
cells after TKI treatment withdrawal (Figure 6H). Our data ob-
tained in five experimental models highlight the usefulness
of FASN inhibition to reverse this malignant adaptation and the
associated acceleratedmetastatic dissemination. These innova-
tive results have clinical implication for the improvement of anti-
angiogenic therapies and provide mechanistic insights into the
intriguing recent clinical data revealing that RTKI treatment break
can be associated with tumor regrowth (Bruce et al., 2014).
In line with previous studies (Ebos et al., 2009a; Pa`ez-Ribes
et al., 2009), sunitinib treatment in preclinical xenograft models
led to an adaptive-evasive response after treatment withdrawal,
but not during treatment administration (Figures 1 and 6H). During
sunitinib treatment of human MDA-MB-231 and HT-29 xeno-
grafts, tumors shrank and metastases were inhibited, whereas
treatmentwithdrawal accelerated tumor regrowth andmetastatic
dissemination to different organs. Similar effects were observed
with a transgenic model of MMTV-PyMT mice and syngeneic
mousemodelsof 4T1andLLC tumors.Histological analysisofpri-
mary tumors after sunitinib treatment and withdrawal show a
restoration of blood vascularization and an increased density of
a-SMApositive cells, butnodifference in inflammatory cell infiltra-
tion and lymphangiogenesis. These phenomena were assessed
by a robust computerized quantification applied to whole-tumor
sections fromat least 15primary tumors per condition (FigureS2).
Importantly, a metabolic shift to de novo lipogenesis after su-
nitinib treatment cessation was indicated by the upregulation of
key enzymes and cytokines involved in lipid metabolism and
cancer progression. Notably, both transcriptomic and proteomic
approaches highlighted the same perturbed pathway, which is
associated with lipid and carbohydrate metabolism. Among
the genes validated by RT-PCR analysis, FASN, perilipin, and
adiponectin were significantly upregulated after sunitinib with-
drawal. Perilipin immunostaining of tumor sections confirmed
the increased presence of lipid droplets in adipocytes inside
W-sunitinib tumors. Adipocyte accumulation is also supported
by enhanced deposition of type VI collagen mainly produced
by these cells (Nakajima et al., 2002).
The strength of our study is its depiction of cancer metabolism
during and after RTKI administration (Figure 6H).Wedemonstrate
that tumors adopt a glycolytic phenotype during RTKI treatment,
whereas after drug withdrawal, tumors shift to lipid metabolism
and TCA activity. RTKIs can have a direct effect on the meta-
bolism of cancer cells and stromal cells, as demonstrated by
the in vitro study (Figure 5). The glycolytic phenotype of D-suniti-
nib tumors during RTKI treatment was supported by an increase
in lactate production, lactate transporter (MCT1 and MCT4)Figure 5. Sunitinib and Sorafenib Induce the Warburg Effect in Cancer
(A) Lactate production was measured by NMR in vitro in medium, and cell ext
sunitinib (5 mM) for 24 or 48 hr. Glucose uptake was evaluated by measuring the
(B) Following the same experimental design in (A), cancer cells were incubated w
(C andD) RT-PCR analysis ofmRNA expression levels of MCT1,MCT4, FASN, PD
or sorafenib (D).
(E and F) Lactate production was measured by NMR in medium from HUVECs a
(G) RT-PCR analysis of mRNA expression levels of MCT1, MCT4, FASN, PDK1,
Data are presented as mean ± SD. *p% 0.05; **p% 0.01.
Celexpression, PDK expression, and a hypoxic microenvironment
resulting from angiogenesis inhibition. These features reflect the
useof anaerobicglycolysis tomeet thebioenergetic needsof pro-
liferation and/or survival, known as the Warburg effect (Feron,
2009). Hypoxia is known to play a critical role in reprogramming
cancermetabolism towardanaerobicglycolysis (i.e., theWarburg
effect) through the induction of PDK and lactate dehydrogenase
(LDH) expression and increased lactate production (Kim et al.,
2006). Indeed, lactate was recently identified as a major energy
source in tumors; the lactate produced by hypoxic tumor cells
may diffuse and be taken up by oxygenated tumor cells (Son-
veaux et al., 2008). In vitro treatment with sunitinib and sorafenib
of fourdifferent cancer cell lines in addition tocancer cells isolated
from MMTV-PyMT induced a rapid and drastic increase in
glucose uptake and lactate production. A significant induction
of PDK1 and PDK2 was also observed in vitro. RTKI- mediated
glycolytic effects were also observed in CAFs and HUVECs, indi-
cating a similar response of stromal cells to therapy. This is in line
with the key role of glycolysis reported in endothelial cells during
angiogenesis (Schoors et al., 2014). Thesedata demonstrate that,
beyond their antiangiogenic effects, RTKIs can directly affect the
metabolism of both cancer and stromal cells.
After RTKI withdrawal (Figure 6H), W-sunitinib tumors dis-
played a metabolic shift toward (1) a decrease in glycolytic en-
zymes, (2) an increase in lipid metabolism and transporter levels,
and (3) an increase in TCA enzyme levels. A decrease in perilipin-
positive cells and low FASN and ACC-amRNA expression levels
were observed during sunitinib administration. Thus, the meta-
bolic shift toward lipogenesis is specific to sunitinib withdrawal
rather than to a direct effect of the RTKI during the treatment.
The moderate increase in lactate levels observed after with-
drawal is likely due to tumor revascularization, which reduces
hypoxia. This finding is consistent with the decrease in PDK1
and PDK2 expression, which also supports increased TCA activ-
ity supplied by pyruvate. In proliferating cells, citrate provided
by increased TCA activity is exported from the mitochondria to
the cytoplasm, where citrate can be converted to the lipogenic
precursors acetyl-CoA and oxaloacetate by ATP citrate lyase
(Feron, 2009). The reduction in glycolysis in the W-sunitinib
tumors and the increase in citrate cycle activity may result in
increased lipids synthesis to sustain tumor proliferation. While
no obvious relative increase in beta-oxydation markers (PPARg
and phoshorylated ACC) was seen in W-sunitinib tumors, the
increased de novo lipid synthesis is likely used as building blocks
for tumor rebound following treatment withdrawal.
The link between therapeutic sensitivity and dysregulated can-
cer cell metabolism is rapidly being dissected (reviewed in Butler
et al., 2013). Lipogenic enzymes, and particularly FASN, have
become an attractive target for therapeutic intervention (Currieand Stromal Cells In Vitro
racts from MDA-MB-231, BT-549, and HCT-116 cancer cells incubated with
glucose levels in medium.
ith 5 mM sorafenib for 24 and 48 hr.
K1, and PDK2 inMDA-MB-231 cells incubated for 24 and 48 hr with sunitinib (C)
nd CAFs incubated with sunitinib (E) or sorafenib (F).
and PDK2 in HUVECs incubated for 24 and 48 hr with sunitinib.
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Cancer Metabolism Shift and Antiangiogenic Drugset al., 2013). The pharmacological inhibition of FASNwith orlistat
completely reversed tumor regrowth and metastatic dissemina-
tion induced by sunitinib withdrawal in five experimental models
(Figures 7 and S6). The treatment of mice with orlistat at the indi-
cated concentration and period did not show a significant differ-
ence in the globalmetabolic profile of sera. This indicates that the
effects observed could not be ascribed to a systemic impact on
thewhole-bodymetabolism, but rather to a shift occurring specif-
ically in the tumors. However, we cannot exclude differences in
some specific metabolites in sera of mice treated with orlistat.
It is worth noting that homeostasis of the blood metabolism is a
highly regulated mechanism and that only urine analysis may
reveal more precisely metabolic changes. In addition, the 5%–
10% weight loss caused by orlistat is likely not high enough to
significantly affect the global metabolic profile of sera. Although
the role of FASN in initial cancer growth is well documented,
our study is the first to provide its implication in malignant adap-
tation to antiangiogenic therapy removal. The key role played
by FASN in the tumor compartment is supported by the use of
shRNA technology in MDA-MB-231 tumors. Importantly, shRNA
FASN completely abolished the tumor regrowth and metastatic
dissemination induced by sunitinib withdrawal in vivo. These ex-
periments clearly show that interfering with tumor FASN is suffi-
cient to overcome the tumor aggressiveness induced by drug
withdrawal, and those results have potential clinical implications.
By providing a detailed metabolic profile of tumor adaptation
during and after RTKI treatment, our study shed light on recent




Human cells from breast cancer (MDA-MB-231 expressing or not expressing
luciferase [LUC+]), BT-549 cells, human colorectal cancer HCT-116 andHT-29Figure 6. Colorectal Cancer Xenograft and Transgenic MouseModel of
of Breast Cancer Xenografts
(A–D) RAG1/mice were injected subcutaneously with HT-29 LUC+ cells and trea
tumor volumes showing an inhibition of tumor growth during sunitinib administratio
Metastasis detection by bioluminescence in organs of vehicle- andW-sunitinib-tre
level measurement by NMR in HT-29 tumors. (C) Representative immunohistoc
100 mm. Quantification of FASN positive cell density and distribution from the bord
same procedure as described in Figures 5A and 5B, lactate production and glu
sorafenib treatment for 24 and 48 hr.
(E–G) MMTV-PyMT mice bearing mammary tumors (50 mm3) were treated with ve
corresponds to the tumor volume evolution. The table indicates the number of tum
its withdrawal (W-sunitinib). (F) H&E staining of lung sections showing metastase
whole-lung sections. Scale bar, 1mm. (G) Representative immunohistochemical im
and stained for FASN (left). Scale bar, 100 mm. Quantification of FASN positive c
(n = 36 tumors for W-sunitinib and n = 31 for vehicle group). Data are presented
(H) Schematic representation of the tumor metabolism shift during and after treatm
tumors), RTKIs can have direct effects on the metabolic process of stromal and
hypoxia. Hypoxic tumors shrink and become hypoxic, leading to an increase in gl
anaerobic glycolysis to sustain their energy needs for survival. Pyruvate dehy
D-sunitinib tumors, which results in the inhibition of pyruvate dehydrogenase (PDH
acid (TCA) cycle and to the accumulation of lactate. Cancer cells overexpress
overexpress MCT4 only in hypoxic conditions imposed by antiangiogenic therap
overexpress MCT1 for the import of lactate and produce high levels of LDH th
W-sunitinib tumors, citrate cycle enzymes are upregulated, and PDK1 and PDK
metabolism, a process associated with the acquisition of a malignant phenotype a
synthesis after sunitinib withdrawal, the acquisition of the malignant phenotype c
CelLUC+, mouse mammary carcinoma 4T1-LUC+, mouse Lewis lung carcinoma
LLC-LUC+ cells expressing luciferase, HUVECs, PyMT mammary carcinoma
epithelial cancer cells, and CAFs isolated from MMTV- PyMT mice were
used. Cell culture and transfection of MDA-MB-231 LUC+ cells with shRNA
against FASN are described in the Supplemental Experimental Procedures.
In Vivo Experiments
Preclinical Models
For human xenografts, MDA-MB-231 LUC+ or HT-29 LUC+ subconfluent cells
were trypsinized, resuspended in serum-free medium (5 3 106 cells/ml), and
mixed with an equal volume of cold Matrigel according to a previous report
(Sounni et al., 2002). Cell suspension (106 cells/400 ml) was injected s.c. into
RAG1/ immunodeficient mice in both flanks. For the syngeneic model,
4T1-LUC+ cell (5 104) suspension in 100 ml Dulbecco’s modified Eagle’s me-
dium (DMEM) was mixed with 100 ml Matrigel and subcutaneously (heterotyp-
ic) injected in Balb/c mice. For orthotopic injections in the MFP, 8-week-old
(n = 8) Balb/c female mice were anesthetized, and 50 ml of cell suspension
(5 3 104 cells) was injected in the mammary gland after a small incision in
the skin (0.5 cm). For the syngeneic model of Lewis lung carcinoma (LLC),
cell (5 3 104) suspensions in 100 ml DMEM were mixed with 100 ml Matrigel
and subcutaneously (heterotypic) implanted in 8-week-old C57BL6 mice. Tu-
mor growth was assessed by measuring the length and width of tumors every
3–4 days. Tumor volumes were estimated as previously described (length 3
width2 3 0.4) (Noe¨l et al., 1993). For in vivo imaging, mice were injected intra-
peritoneally with 75 mg/kg D-luciferin (Caliper Life Sciences), anesthetized
with isofluorane, and then imaged. Animals were imaged once a week, and or-
gans were imaged at sacrifice. Imaging was performed using a Lumina II IVIS
(in vivo imaging system) instrument (Caliper Life Sciences) with biolumines-
cence quantification using Living Image software (Caliper Life Sciences) ac-
cording to manufacturer’s recommendations. All animal procedures with small
animals were performed according to the Federation of European Laboratory
Animal Sciences Associations (FELASA) and local ethical committee at Univer-
sity of Liege (Belgium). Animals were housed within the accredited animal
facility of GIGA located at the CHU Sart Tilman (University of Liege, Belgium).
Drug administration and experimental groups are described in detail in the
Supplemental Experimental Procedures.
Primary Cell Isolation and Culture
Extraction and specific isolation of CAFs and PyMT epithelial cancer cells are
described in the Supplemental Experimental Procedures.Mammary Carcinoma Recapitulate the Tumor Adaptation Response
ted daily with suninitib (40mg/kg) for 30 days (from day 7 to 37). (A) Evolution of
n and a rapid tumor regrowth after sunitinib treatment withdrawal (W-sunitinib).
ated animals (right). Data are presented asmean ± SEM (p% 0.01). (B) Lactate
hemical images of primary HT-29 tumors stained for FASN (left). Scale bar,
er to the center of the tumors (right) (n = 12 tumors per group). (D) Following the
cose uptake of HT-29 cells were evaluated in vitro in response to sunitinib or
hicle (n = 6) or sunitinib (n = 7) from day 55 to day 76 (after birth). (E) The graph
ors (T) of different sizes at the end of sunitinib treatment (D-sunitinib) and after
s. The graph corresponds to computerized quantification of metastasis size on
ages of mammary tumors fromMMTV-PyMTmice treated or not with sunitinib
ell density and distribution from the border to the center of the tumors (right)
as mean ± SD. *p% 0.05; **p% 0.01; ***p% 0.001.
ent with angiogenesis inhibitor (RTKIs). Left: during drug treatment (D-sunitinib
cancer cells in an autonomous manner or indirect effects through induction of
ucose consumption as revealed by lactate formation. Tumors preferentially use
drogenase kinase-1 and -2 (PDK1 and PDK2) expressions are increased in
) and the consequent blockade of aerobic glucose oxidation in the tricarboxylic
both MCT1 for lactate uptake and MCT4 for lactate export and stromal cells
y. Right: after drug withdrawal (W-sunitinib tumors), vascularized tumors still
at convert lactate to pyruvate and vice versa. While glycolysis is inhibited in
2 expressions are increased. In W-sunitinib tumors, cells adapt toward lipid
fter sunitinib treatment withdrawal. Our working model is that by blocking lipid
an be blocked, restoring the beneficial effects of sunitinib.
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Cancer Metabolism Shift and Antiangiogenic DrugsRNA Extraction, Semiquantitative RT-PCR, andMicroarray Analyses
See the Supplemental Experimental Procedures for details.
Proteomic Analysis
Preparation of tumor extracts for western blot and label-free mass spec-
trometry quantification are described in the Supplemental Experimental
Procedures.
Nuclear Magnetic Resonance Analyses
Sample preparation and NMR measurements are described in detail in the
Supplemental Experimental Procedures.
Immunohistochemistry
Detailed procedures for IHC and computerized quantification are described in
the Supplemental Experimental Procedures.
Statistical Analysis
Mann-Whitney test, one-way ANOVA test, and t test were used as described
in the Supplemental Experimental Procedures. The error bars represented in
each figure aremean ± SDormean ± SEM, and respective analysis is indicated
in the figure legends. p < 0.05 was considered statistically significant.
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